Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses advancements in breast cancer treatment, highlighting CDK4/6 inhibitors and ...

The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.

EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Saturday, October 19, 202 ...

On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...

The European Commission is expected to make a decision on Kisqali's approval in this setting in the next two months.

Novartis on Friday announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...